Summit Therapeutics, Inc. (SMMT)
14.28
+0.16
(+1.17%)
USD |
NASDAQ |
Jun 09, 16:00
13.22
-1.06
(-7.39%)
After-Hours: 20:00
Summit Therapeutics SG&A Expense (Quarterly) : 62.59M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 101.25M |
| Denali Therapeutics, Inc. | 33.51M |
| NovelStem International Corp. | 0.005M |
| Brainstorm Cell Therapeutics, Inc. | 1.284M |
| Kezar Life Sciences, Inc. | 5.208M |